LS Mean ANC, ALC, AMC, and WBC counts from baseline (week 0) to 52 weeks (ITT population). (A) LS Mean ANC over post–dose dense sampling period. (B) LS Mean ALC over post–dose dense sampling period. (C) LS Mean AMC over post–dose dense sampling period. (D) LS Mean WBC counts over post–dose dense sampling period. All P values are nominal. At week 52, 3 of 17 participants receiving placebo were given mavorixafor in advance of their week 52 assessments as they entered the open-label portion of the trial. One participant receiving mavorixafor did not take mavorixafor at week 52. Some samples collected were not measurable; 3 participants in the mavorixafor group discontinued mavorixafor treatment.